Scientists in Canada have 3D-printed viable human testicular cells that they hope will eventually yield sperm from patients with forms of infertility that currently cannot be treated.
Scientists in Canada have 3D-printed viable human testicular cells that they hope will eventually yield sperm from patients with forms of infertility that currently cannot be treated.
Technological developments of the 3D Bioprinters and increasing investment in R & D of stem cell and regenerative medicines are driving the demand of the market. The global3D Bioprinting Marketis expected to reach USD 2,687.8 million by 2027, according to a new report by Emergen Research
PHILADELPHIA The American Association for Cancer Research (AACR) today announced its newly elected class of Fellows of the AACR Academy.
ReportLinker The growth of this market is majorly driven by the growing awareness about the benefits of cell-based vaccines, increasing demand for monoclonal antibodies (mAbs), funding for cell-based research, growth in stem cell research, the launch of new cell culture media by market players, and the growing focus on personalized medicine. New York, March 22, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cell Culture Media Market by Type, Application, Diagnostics, Tissue Engineering), End User - Global Forecast to 2026" - https://www.reportlinker.com/p06246587/?utm_source=GNW On the other hand, the high cost of cell biology research is restraining the growth of this market. The serum-free media segmentaccounted for the highest growth rate in the cell culturemedia market, bytype, during the forecast periodIn 2020, the serum-free media segment accounted for the largest share of the market.
Dosing will soon start in a Phase 1/2 trial of GPH101, an experimental gene-editing therapy designed to correct the genetic mutation that causes sickle cell disease (SCD). The first participant had been enrolled in the study late last year, but due to the recent surge of the SARS-CoV-2 Omicron variant, the virus that causes COVID-19, dosing was delayed
ATLANTA--(BUSINESS WIRE)--Axion BioSystems, a leading life sciences tools company focused on advanced live-cell assay systems, announces the acquisition of the Netherlands-based CytoSMART Technologiesan innovator in kinetic live-cell imaging analysis. The collaboration positions Axion for significant expansion in the fields of stem cell research, immuno-oncology, cell-based therapies, and drug discovery
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has been awarded a $2 million SBIR Phase II grant from the National Institute of General Medical Sciences, a division of the National Institutes of Health. Awarded through a competitive process, the two-year grant will support the development of cell engineering methods that are designed to reprogram a patients own immune cells directly into dopamine-producing neurons, a potential novel therapeutic approach for the treatment of Parkinsons disease
REDWOOD CITY, Calif., March 21, 2022 (GLOBE NEWSWIRE) --Jasper Therapeutics, Inc.
The Regenerative Therapies Market research provides a clear understanding of the markets major geographies, and also the key segments and sub-segments. The study focuses on the state of regional development, including sales volume, cost, and growth volume. The report also gives detailed company descriptions of leading players in the Regenerative Therapies industry that are included in Regenerative Therapies Market.
Mantle cell lymphoma is a difficult cancer type with high relapse rates, but novel targeted approaches such as CAR T-cell therapy hold promise for more successful response rates in the future. First-line treatment strategies for mantle cell lymphoma (MCL) currently range from intensive chemotherapy and autologous stem cell transplant (ASCT) to combination regimens and novel targeted therapies. As chimeric antigen receptor (CAR) T-cell therapies change the treatment landscape in other hematological cancer types, a recent review sees potential for this novel strategy to improve outcomes for MCL.
Recent Comments